The FDA approved a new injected version of the cancer immunotherapy drug Keytruda. With injections, patients need only an hour total for treatment, while Keytruda infusion may require two hours.

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

Merck & Co. is set to report fourth-quarter earnings on Tuesday before the market opens, with investors scrutinizing whether the pharmaceutical giant can articulate a credible growth story as its ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

As Merck MRK is gearing up to report its fourth-quarter and full-year 2025 results on Feb. 3, investors' focus is likely to be on the sales performance of its blockbuster cancer drug, Keytruda. The ...

Former President Jimmy Carter credits the new cancer drug Keytruda for shrinking his brain tumors completely. It's one more victory for the newest class of cancer drugs that empower the immune system ...